

August 16, 2022

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E), Mumbai - 400 051

Scrip Code: **543271**

Trading Symbol: **JUBLINGREA**

Subject: Intimation of Investor/ Analyst Meetings

Dear Sirs,

Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the management of the Company shall be participating in 'Edelweiss India Conference, 2022, Singapore' physical Investor meetings to be held on Thursday, August 18, 2022 and Friday, August 19, 2022 in Singapore. The details of the Investors/Analysts are as under:

BlackRock Asia	AMIRAL GESTION	Nippon Offshore
White Oak Capital	Somerset Capital	Victory Capital
First State Investments	Maybank Asset Management Singapore Pte Ltd	Dymon Asia
Goldman Sachs Asset Management	Amansa Investment Advisors Pvt Ltd	Templeton Emerging Markets Group

The schedule may undergo change due to exigencies on the part of Investors/Analysts/Company.

We also enclose the presentation to be used during the conference.

This is for your information and records.

Thanking you,

Yours faithfully,
For Jubilant Ingrevia Limited

Deepanjali Gulati
Company Secretary



**JUBILANT
INGREVIA**

Investor Presentation

August 2022

Disclaimer



Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Effective 1st February 2021, Life Science Ingredients business of Jubilant Pharmova Limited (earlier Jubilant Life Sciences Limited) demerged to Jubilant Ingrevia Limited and post demerger the consolidated financial results of the Jubilant Ingrevia Limited for the quarter and the year ended 31 March 2021 comprised results only for two months of operations, starting from 1st February 2021 .

To provide the comprehensive picture of the operations of the Company on continuing basis the results for previous periods has been presented on Pro-forma basis by using relevant portion of the published results of LSI Segment - Jubilant Pharmova Limited on Pro-forma basis as Under :

- **Results for Full year FY21 has been derived on Pro-forma basis from the reported discontinued operations results for LSI segment of Jubilant Pharmova Limited and Audited results for Jubilant Ingrevia Limited as under :**
 - **For FY 21 by combining the results from 01 April 2020 to 31 January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited and for Q4'FY21 by combining the results for January 2021 from the reported discontinued operations for LSI segment of Jubilant Pharmova Limited and Results from Feb 21 to March 21 from the Audited results of Jubilant Ingrevia Limited**
- **EPS for previous periods has been computed assuming existence of share capital throughout the period**

NOTES:

1. *The numbers for the quarter and Financial year have been reclassified and regrouped wherever necessary*
2. *Closing Exchange Rate for USD 1 at Rs 77.18 as on June 30, 2022*

Company Overview



Jubilant Bhartia Group - Snapshot



Jubilant Bhartia Group founded by Shyam S Bhartia and Hari S Bhartia, leading industrialists from India



Strong presence in diverse sectors like Pharmaceuticals, CDMO (Contract Research & Development Services) and Therapeutics, Specialty Chemicals, Nutraceutical Products and other Life Science Products, Performance Polymers, Food Service (QSR), Auto, Consulting in Aerospace and Oilfield Services







Global presence through investments in India, USA, Canada, Europe, Singapore, China, Sri Lanka and Bangladesh




Employs around 46,000 people across the globe with Over 2,400 in North America

Integrated Business Model



Glorious Four Decades of Growth

Our Journey



Company Snapshot




Leadership

- Globally # 1 in 17 Pyridine Derivatives
- Globally among Top 2 in (Pyridine + Beta)
- Global Leadership in Niacinamide; Globally among top 2 in Vitamin B3 (Niacin & Niacinamide)
- Leader in India Vitamin B4 (Choline Chloride)

Globally

- Amongst top 2 in Acetic Anhydride
- Largest manufacturer of bio-based Acetaldehyde

Revenue Segmentation: By Region (FY'22)



Total **1500+** customers

- Speciality Chemicals: **470**
- Nutrition & Health Solutions: **460**
- Chemical Intermediates: **570**


Total **125+** products

- Speciality Chemicals: **70+**
- Nutrition & Health Solutions: **48**
- Chemical Intermediates: **9**

Sales in over **50** countries with **1/3rd** of sales in regulated markets such as US, Europe, Japan - leading to sustainable revenue

Diverse Industry End-Use

FY'22 Revenue Split



FY 22 Revenue
 ₹ 4,944 Cr/USD 641 Mn
EBITDA ₹ 863 Cr/
USD 112Mn (17.4%)
Net Debt / EBITDA 0.21x

Expertise in **35 Technology platforms** which include Acetyl, Pyridine/ Piperidine, Ketene/ Diketene, Halogenation & others (At large commercial scale)

Expertise in handling **multi-step chemistries** (Up to ~13 steps) At Commercial scale

Strong Corporate Governance, Quality regulatory & Compliance

In line with our Vision to double the Revenue by FY'26, we have **60+ Products** in Pipeline.

5 Global scale Manufacturing sites with **50** plants

Global workforce of **~2100** employees

Offices in **India, US, Europe, Japan & China**

Executive Leadership Team



Rajesh Srivastava
Chief Executive Officer &
Managing Director
*35 years of
industry experience*



Anil Khubchandani
Co-CEO & WTD
Speciality Chemicals
*30 years of industry
experience*



Chandan Singh
Co-CEO
Chemical Intermediates
*36 years of industry
experience*



Sumit Das
SVP – Nutrition &
Health Ingredients
*30 years of industry
experience*



Ashish Kumar Sinha
VP – Animal & Human
Nutrition & Health Solutions
*24 years of industry
experience*



Prakash Bisht
President &
Chief Financial Officer
*33 years of
industry experience*



Vijay Kumar Srivastava
President – Chief of
Operations
*23 years of industry
experience*



Vinita Koul
SVP &
Head- HR
*26 years of industry
experience*



Prasad Joglekar
EVP & Head –
Supply Chain
*29 years of industry
experience*

Leadership team has an average ~ 30 years of industry experience

Multi Location Manufacturing & Operation Excellence



Manufacturing Facilities



463 acres

Gajraula, Uttar Pradesh, India

Integrated facility for Speciality Chemicals & Chemical Intermediates



310 acres

Bharuch, Gujarat, India

Speciality Chemicals, Nutrition & Health Ingredients & Chemical Intermediates facility located in SEZ



144 acres

Nira, Maharashtra, India

Chemical Intermediates



109 acres

Samlaya, Gujarat, India

Animal Nutrition & Health Solutions



3.5 acres

Ambernath, Maharashtra, India

Speciality Chemicals

We operate 50 Plants across 5 sites in 3 states

We have enough land available at our existing sites for future expansions

Operation Highlights

Multi-Chemistry, Multi-Product and Process Condition handling expertise

Large capacities in **Continuous & Batch processes**

World Class GMP facility at Bharuch

Temp, Humidity & Differential Pressure Controlled Areas with ISO-8 (Class 100,000) Clean rooms

cGMP compliant Pilot Plant

20 – 1000L Reactors (Glass Assemblies, Cryogenic & Plug Flow reactors, Lyophilizer Autoclaves)

In-house Utilities

Captive Power Plant (Gajraula), Own Steam Generating Boilers, Chilled Water & Brine Unit

Ecologically Harmonized Practices

Incinerators, ETPs, Multi Effect Evaporators, Reverse Osmosis, Water Polishing Plants

Health & Safety: benchmarking global performance by Chilworth Dekra- FY'07 & Chola MS- FY'21

Compliance: 3,800+ compliance items through 'EY' Conformity tool

Research Development & Technology (RDT)

Key Highlights



3 RDT centers in Noida, Gajraula and Bharuch



35 Key technology platforms developed & commercialized to global standards. Some are unique: Ammoxidation, Grignard etc.



92 highly qualified scientists (22 PhDs)



60+ Products in Pipeline for next 4 years

Key Technology Platforms

1000s MT		100s MT			MTs	
Aromatization	Oxidation	Sandmeyer	Grignard	Fluorination	Hoffmann	Bu-Li
Vapour Phase Reactions	Ammoxidation,	Bromination	Methylation	Thiol Handling	Re-arrangement	Reaction
Chlorination / Photo chlorination	Fermentation	Esterification	Quarternisation	Ethylene Oxide Reaction	Methoxylation	Iodination
	Ketene Technology	Hydrogenation	Chichibabin		N-Formylation	Chiral Synthesis
						De-alkylation

Key focus areas for RDT

- **Optimization** Existing product's processes to remain globally competitive
- **Expansion** Focus on **Agro, Nutrition CDMO & Antimicrobials**– New Product Development
- **Academic Collaboration** **New technologies by academia collaboration**/expanding internal infrastructure
- **Scientific Advisory Board** **Strong Scientific advisory board** to support RDT
- **Centre of Excellence** For Bio catalysis, Flow chemistry, Chemo catalysis, Gas phase Catalytic Chemistry

End Usage Applications for Pharma, Agrochemicals & Nutraceuticals



Off- Patented Pharma (APIs)	Therapeutic Category (Used in ~ 53 APIs)			Our Product Category (GMP & Non-GMP)		
	Antipyretic	Analgesic	Antifibrosis	Pyridine, Picolines	Amino Methyl Pyridines	Chloro/ Bromo/ Fluoro Pyridines
Patented Pharma (APIs)	Anti inflammatory	Anticoagulant	Anticonstipation	Amino Pyridines	Hydroxy Methyl Pyridine	Piperidine
	Antibiotics	Anti viral	Anesthetic	Acetic Anhydride	Methyl Ethyl Pyridine	Pyridine Aldehyde
Agrochemical & Antimicrobial	Antihistamine	Antidiabetic	Green Solvent	Azacyclonol	Lutidines & Collidines	Ethyl Acetate
	Therapeutic Category (Used in ~ 12 APIs)			Our Product Category (GMP & Non-GMP)		
Nutraceuticals	Antimalarial	Antidiabetic	Anti Cancer	Dichloro pyridine	Halo Azaindole	AminoChloro & Methylpyridine
	Antiretroviral	Anticoagulant	Breast Cancer	Amino Pyrrole Derivative	Hydroxy Methylpyridine	Amino Piperidine derivative
Nutraceuticals	Anti ulcerative	Anti viral	Anti fibrosis	Pyridine, Picolines	Acetic & Propionic Anhydride	
	Used in ~ 23 Actives			Amino Pyridines	Cyano Pyridines	
Nutraceuticals	Insecticide	Fungicide		Halo Pyridines	Acetic & Propionic Anhydride	
	Herbicide	Antimicrobial		Chloro Methyl Pyridines	Pyrithiones Family	
Nutraceuticals	Nutraceutical ingredients:			Niacin/ Niacinamide (Vitamin B3), Choline Chloride (Vitamin B4), RPS, Picolinates & Hexanicotinate		
	Animal Health Solutions : Liver protection, Better Meat quality, Anti-stress, Egg quality enhancer, Gut health solutions, Immunity Enhancer			Various Nutritional premixes		



Financial Highlights: Q1 FY'23

Chairmen's Message on Q1'FY23 Financial Results



Mr. Shyam S Bhartia
Chairman



Mr. Hari S Bhartia
Co-Chairman

"We are glad to announce steady operational and financial performance in Q1'FY23, in the backdrop of inflationary headwinds leading to higher raw material and energy costs during the quarter.

*In our **Specialty Chemicals Business** revenue grew 26% YoY, on account of strong demand across all our product segments. We witnessed significant increase in input costs including energy costs, which was passed on partially during the quarter, impacting segment's EBITDA margin.*

*In our **Nutrition & Health Solution business**, Niacinamide sales volume were significantly impacted due to spread of Avian and Swine Flu in EU and US regions leading to lower segment revenue and EBITDA, however the price realization was better during the quarter. This is a short-term challenge in the segment, and business continues to maintain its market share and leadership position.*

*Our **Chemical Intermediates Business**, continue to witness strong demand resulting into volume growth. Business is maintaining the leadership position of Acetic Anhydride in Domestic market and also Improving our market share in Europe. On YoY basis segment has witnessed normalization of market situation and lower Acetic Acid prices, which is also reflecting into both Revenue and EBITDA.*

We are fully committed towards our growth aspirations and we are excited to realise the emerging opportunities going forward in all our business segments. We are fully confident of moving ahead with our well defined growth capex plan , which is supported by our internal accruals. Our aim is to achieve sustainable profitable growth in medium term and structurally we are poised towards moving on to the next tier of performance in our growth journey and margins".

Financial Highlights¹ : Key Financial Parameters (USD Million)



Period	Sales	EBITDA	EBITDA (%)	PAT	PAT (%)	EPS
Highlights FY22	USD 641 Mn.	USD 112 Mn.	17.4%	USD 62 Mn.	9.6%	USD 0.39
	↑ 42% YoY	↑ 38% YoY	↓ (50) bps	↑ 51% YoY	↑ 58 bps	↑ 51% YoY
Highlights FY21²	USD 452 Mn.	USD 81 Mn.	17.9%	USD 41 Mn.	9.1%	USD 0.26
Highlights Q1'FY23	USD 151 Mn.	USD 20 Mn.	12.9%	USD 10 Mn.	6.8%	USD 0.06
	↑ 2% YoY	↓ (47)% YoY	↓ (1,217) bps	↓ (53)% YoY	↓ (789) bps	↓ (53)% YoY
Highlights Q1'FY22	USD 148 Mn.	USD 37 Mn.	25.1%	USD 22 Mn.	14.7%	USD 0.14

1. All figures are in USD Million unless otherwise stated, translated on Convenience Conversion basis : USD 1 = Rs 77.18

Financial Highlights¹ : Key Financial Parameters (Rs Crore)



Highlights FY22	₹ 4,949 Cr. Sales	₹ 863 Cr. EBITDA	17.4% EBITDA (%)	₹ 477 Cr. PAT	9.6% PAT (%)	₹ 30.0 EPS
	↑ 42% YoY	↑ 38% YoY	↓ (50) bps	↑ 51% YoY	↑ 58 bps	↑ 51% YoY
Highlights FY21 ²	₹ 3,491 Cr. Sales	₹ 627 Cr. EBITDA	17.9% EBITDA (%)	₹ 316 Cr. PAT	9.1% PAT (%)	₹ 19.9 EPS
Highlights Q1'FY23	₹ 1,166 Cr. Sales	₹ 151 Cr. EBITDA	12.9% EBITDA (%)	₹ 79 Cr. PAT	6.8% PAT (%)	₹ 5.0 EPS
	↑ 2% YoY	↓ (47)% YoY	↓ (1,217) bps	↓ (53)% YoY	↓ (789) bps	↓ (53)% YoY
Highlights Q1'FY22	₹ 1,145 Cr. Sales	₹ 287 Cr. EBITDA	25.1% EBITDA (%)	₹ 168 Cr. PAT	14.7% PAT (%)	₹ 10.6 EPS

1. All figures are in Rs Crore unless otherwise stated


Jubilant Ingrevia – Q1 FY'23 Financial Results Summary (USD Million)

Particulars ¹	Q1'FY22	Q1'FY23	YoY (%)
Revenue			
Speciality Chemicals	39.5	49.6	26%
Nutrition & Health Solutions	21.6	19.5	(10%)
Chemical Intermediates	87.2	82.0	(6%)
Total Revenue from Operations	148.3	151.1	2%
Reported EBITDA	37.2	19.6	(47%)
Speciality Chemicals	10.9	8.3	(24%)
Nutrition & Health Solutions	3.4	2.4	(29%)
Chemical Intermediates	23.8	9.9	(58%)
Unallocated Corporate (Expenses)/Income	-0.9	-1.1	-
PAT	21.8	10.3	(53%)
EPS	0.14	0.06	(53%)
Reported EBITDA Margins	25.1%	12.9%	
Speciality Chemicals	27.7%	16.8%	
Nutrition & Health Solutions	15.9%	12.5%	
Chemical Intermediates	27.3%	12.1%	
Net Margin	14.7%	6.8%	


FINANCIAL HIGHLIGHTS

- Overall Revenue grew by 2% on YoY basis, mainly due to higher sales performance by Speciality Chemical Business.
- Speciality Chemicals revenue grew by 26% YoY driven by volume growth across product segments
- Nutrition and Health Solutions business performance was impacted mainly due to spreading of Bird & Swine Flu in EU & US region resulting into lower demand. This is a short-term challenge in the segment, and business continues to maintain its market share and leadership position.
- Chemical Intermediates volume have grown while revenue is impacted mainly due to lower prices of key RM i.e. Acetic Acid.
- EBITDA at USD 19.96 Mn, is lower by 47%, mainly due to Chemical Intermediate EBITDA normalization. Nutrition Margins were impacted due to lower sale, while Speciality Margins were impacted due to higher input costs which were passed on partially .
- PAT declined by 53% YoY driven by lower EBITDA, as explained above.
- ROCE for the quarter stood at 20.8% as against 27.8% in FY22 on TTM Basis
- ROE during the quarter stood at 15.7% as against 21.9% in 'FY22 on TTM basis

Q1'FY23 Geographical Revenue Split



Q1'FY23 Industry End-Use Split



1. All figures are in USD Million unless otherwise stated, translated on Convenience Conversion basis : USD 1 = Rs 77.18


Jubilant Ingrevia – Q1 FY'23 Financial Results Summary (Rs Crore)

Particulars ¹	Q1'FY22	Q1'FY23	YoY (%)
Revenue			
Speciality Chemicals	305	382	26%
Nutrition & Health Solutions	167	150	(10%)
Chemical Intermediates	673	633	(6%)
Total Revenue from Operations	1,145	1,166	2%
Reported EBITDA	287	151	(47%)
Speciality Chemicals	84	64	(24%)
Nutrition & Health Solutions	27	19	(29%)
Chemical Intermediates	184	76	(58%)
Unallocated Corporate (Expenses)/Income	-7	-8	-
PAT	168	79	(53%)
EPS	10.6	5.0	(53%)
Reported EBITDA Margins	25.1%	12.9%	
Speciality Chemicals	27.7%	16.8%	
Nutrition & Health Solutions	15.9%	12.5%	
Chemical Intermediates	27.3%	12.1%	
Net Margin	14.7%	6.8%	


FINANCIAL HIGHLIGHTS

- Overall Revenue grew by 2% on YoY basis, mainly due to higher sales performance by Speciality Chemical Business.
- Speciality Chemicals revenue grew by 26% YoY driven by volume growth across product segments
- Nutrition and Health Solutions business performance was impacted mainly due to spreading of Bird & Swine Flu in EU & US region resulting into lower demand. This is a short-term challenge in the segment, and business continues to maintain its market share and leadership position.
- Chemical Intermediates volume have grown while revenue is impacted mainly due to lower prices of key RM i.e. Acetic Acid.
- EBITDA at Rs 151 Crore is lower by 47%, mainly due to Chemical Intermediate EBITDA normalization. Nutrition Margins were impacted due to lower sale, while Speciality Margins were impacted due to higher input costs which were passed on partially .
- PAT declined by 53% YoY driven by lower EBITDA, as explained above.
- ROCE for the quarter stood at 20.8% as against 27.8% in FY22 on TTM Basis
- ROE during the quarter stood at 15.7% as against 21.9% in 'FY22 on TTM basis

Q1'FY23 Geographical Revenue Split



Q1'FY23 Industry End-Use Split




1. All figures are in Rs Crore unless otherwise stated


Jubilant Ingrevia – FY'22 Financial Results Summary (USD Million)

Particulars ¹	FY21 ²	FY22	YoY (%)
Revenue			
Speciality Chemicals	145.6	180.4	24%
Nutrition & Health Solutions	81.6	99.4	22%
Chemical Intermediates	225.1	361.4	61%
Total Revenue from Operations	452.3	641.3	42%
Reported EBITDA	81.2	111.9	38%
Speciality Chemicals	34.8	40.5	16%
Nutrition & Health Solutions	16.9	21.3	26%
Chemical Intermediates	30.6	54.0	77%
Unallocated Corporate (Expenses)/Income	-1.0	-3.9	278%
PAT	41.0	61.8	51%
EPS	0.3	0.4	51%
Reported EBITDA Margins	17.9%	17.4%	
Speciality Chemicals	23.9%	22.4%	
Nutrition & Health Solutions	20.7%	21.4%	
Chemical Intermediates	13.6%	14.9%	
Net Margin	9.1%	9.6%	

FY22 Geographical Revenue Split



FY22 Industry End-Use Split



FINANCIAL HIGHLIGHTS

- Revenue grew by 42% on YoY basis, driven by growth across Business segments.
- Speciality Chemicals revenue grew by 24% YoY driven by volume and price growth across products.
 - Speciality Chemical Volume grew by 16% on YoY basis.
- Nutrition and Health Solutions revenue grew by 22% YoY driven by higher volumes and as well as higher prices.
 - Niacinamide volume grew by 9% on YoY basis.
- Chemical Intermediates revenue grew by 61% YoY, Overall driven by higher prices and favorable market conditions, during the majority part of the financial year.
 - Acetic Anhydride Volume grew by 3% on YoY basis.
- EBITDA at USD 111.9 Million, grew by 38% on account of strong performance of all the three product segments.
- PAT grew by 51% YoY driven by growth in EBITDA, aided by reduction in finance cost on account of reduction in Debt and optimization of Interest rates.
- ROCE in FY22 improved to 27.8 % against 20.2% in FY21
- ROE in FY22 stood at 21.9% as against 16.4% in FY21.

1. All figures are in USD Million unless otherwise stated, translated on Convenience Conversion basis : USD 1 = Rs 77.18
 2. FY21 is derived on Pro-forma basis by combining reported discontinued operation results of LSI segment of Jubilant Pharmova Limited and audited results of company as explained in Slide 2
 - EPS has been computed on combined profits assuming existence of share capital for full period.

Jubilant Ingrevia – FY'22 Financial Results Summary (Rs Crore)


FINANCIAL HIGHLIGHTS

- Revenue grew by 42% on YoY basis, driven by growth across Business segments.
- Speciality Chemicals revenue grew by 24% YoY driven by volume and price growth across products.
 - Speciality Chemical Volume grew by 16% on YoY basis.
- Nutrition and Health Solutions revenue grew by 22% YoY driven by higher volumes and as well as higher prices.
 - Niacinamide volume grew by 9% on YoY basis.
- Chemical Intermediates revenue grew by 61% YoY, Overall driven by higher prices and favorable market conditions, during the majority part of the financial year.
 - Acetic Anhydride Volume grew by 3% on YoY basis.
- EBITDA at Rs 863 Crore, grew by 38% on account of strong performance of all the three product segments.
- PAT grew by 51% YoY driven by growth in EBITDA, aided by reduction in finance cost on account of reduction in Debt and optimization of Interest rates.
- ROCE in FY22 improved to 27.8 % against 20.2% in FY21
- ROE in FY22 stood at 21.9% as against 16.4% in FY21.


- All figures are in Rs Crore unless otherwise stated
- FY21 is derived on Pro-forma basis by combining reported discontinued operation results of LSI segment of Jubilant Pharmova Limited and audited results of company as explained in Slide 2
- EPS has been computed on combined profits assuming existence of share capital for full period.

Particulars ¹	FY21 ²	FY22	YoY (%)
Revenue			
Speciality Chemicals	1,124	1,393	24%
Nutrition & Health Solutions	630	767	22%
Chemical Intermediates	1,738	2,789	61%
Total Revenue from Operations	3,491	4,949	42%
Reported EBITDA	627	863	38%
Speciality Chemicals	268	312	16%
Nutrition & Health Solutions	130	164	26%
Chemical Intermediates	236	417	77%
Unallocated Corporate (Expenses)/Income	-8	-30	278%
PAT	316	477	51%
EPS	19.9	30.0	51%
Reported EBITDA Margins	17.9%	17.4%	
Speciality Chemicals	23.9%	22.4%	
Nutrition & Health Solutions	20.7%	21.4%	
Chemical Intermediates	13.6%	14.9%	
Net Margin	9.1%	9.6%	

FY22 Geographical Revenue Split



FY22 Industry End-Use Split



Debt Profile – As on 30th June, 2022 (USD Million)

Particulars ¹	30-Jun-21	31-Mar-22	30-Jun-22
Long Term Borrowings	29.4	13.0	-
Short Term Borrowings	29.8	16.7	36.9
Total Gross Debt	59.2	29.7	36.9
Cash & Equivalent	9.1	6.3	7.4
Total Net Debt	50.1	23.4	29.6
YoY change		-58%	-41%

- We have successfully reduced our high cost long term borrowing resulting into lower blended interest rate of 5.72% in Q1'FY23, as against 7.09 % in Q1'FY22.
- CRISIL Ratings has revised its outlook on the long-term Debt of Jubilant Ingrevia Ltd to now 'Positive' from earlier 'Stable', while reaffirming the rating at 'CRISIL AA' in May'22.

Debt Profile – As on 30th June, 2022 (Rs Crore)


Particulars ¹	30-Jun-21	31-Mar-22	30-Jun-22
Long Term Borrowings	227	100	-
Short Term Borrowings	230	129	285
Total Gross Debt	457	229	285
Cash & Equivalent	70	49	57
Total Net Debt	386	181	228
YoY change		-58%	-41%

- We have successfully reduced our high cost long term borrowing resulting into lower blended interest rate of 5.72% in Q1'FY23, as against 7.09 % in Q1'FY22.
- CRISIL Ratings has revised its outlook on the long-term Debt of Jubilant Ingrevia Ltd to now 'Positive' from earlier 'Stable', while reaffirming the rating at 'CRISIL AA' in May'22.


Balance Sheet – Key Parameters/Ratios (Pro-Forma²)




Return On Capital Employed (RoCE)




Return on Equity



Asset / Turnover and Return On Asset (RoA)



Net Working Capital



1. Figures are in Rs Crore or USD Million unless otherwise stated
2. FY21 is derived on Pro-forma basis by combining reported discontinued operation results of LSI segment of Jubilant Pharmova Limited
3. # The Net Working Capital %age to Turnover & No of days on the basis of Q4'FY22 Annualized Turnover are 15.5% & 56 Days respectively
4. ## RoCE & ROE for the Quarter on TTM basis
5. Rs to USD Translation done on Convenience Conversion basis : USD 1 = Rs 77.18



▪ Increase in Net Working Capital is driven by short term decisions to maintain higher inventory to manage uncertainty of market & supply chain.

BUSINESS SEGMENTS OVERVIEW



Speciality Chemicals – Segment Snapshot

<p>70+ Products (Pyridines & Picolines, Cyanopyridines, Piperidines, Aminopyridines, Lutidines; Diketene derivatives)</p>	<p>Globally among Top 2 in (Pyridine+Beta); Globally #1 in 17 Pyridine Derivatives</p>	<p>Globally lowest cost producer of Pyridine offering significant long term advantage</p>
<p>Market size Jubilant Products: ~ \$1470 Mn Jubilant's Share: 13%</p>	<p>26 plants across 3 Sites</p>	<p>Products are REACH, HALAL & KOSHER certified</p>



- Serving 15 of top 20 Global Pharma & 7 of top 10 Global Agrochemical companies
- International reach through offices in US, Europe, Japan & China
- Around 42% export in regulated markets leading to sustainable revenue
- In line with our Vision to double the Revenue by FY'26, we have **36 Products** in Pipeline.
- Investment target of ~**INR 1,230 Crores/ USD 159.4 Mn** by FY'25

Speciality Chemicals Segment Highlights – Q1 FY’23 (USD Million)

Particulars ¹	Q1'FY22	Q1'FY23	YoY (%)
Revenue	39.5	49.6	26%
Reported EBITDA	10.9	8.3	(24%)
Reported EBITDA Margin (%)	27.7%	16.8%	

FINANCIAL HIGHLIGHTS

- Specialty Chemicals revenue grew by 26% on YoY basis driven by higher volume across product segments
- Specialty Volumes grew by 24% YOY basis
- Share of revenue to customers having Agro Chemical end use grew significantly.
- We also witnessed healthy demand for Oil field chemicals.


EBITDA:

- Segment EBITDA & Margin was lower mainly due to unprecedented and sharp increase in input costs including energy cost, which was passed on partially during the quarter.


BUSINESS HIGHLIGHTS

- Signed a CDMO contract worth Rs.270 Cr with a pharma innovator company to supply of two GMP intermediates.
- Our CDMO Pipeline is healthy and progressing positively. Our new GMP and non-GMP facilities which are expected to be ready during Q3FY’23, will help us in capture growing demand of CDMO projects.
- We observed positive traction of demand for our other Specialty chemicals also from both domestic as well as international customers due to China plus one strategy.

Q1'FY23 Geographical Revenue Split



Q1'FY23 Industry End-Use Split



*Industrial include Paints & Coatings, Print & Packaging, Solvents etc.
 **Consumer include Personal Care, Fragrances etc.

1. All figures are in USD Million unless otherwise stated, translated on Convenience Conversion basis : USD 1 = Rs 77.18
 2. Specialty Chemicals Segment comprises Specialty Ingredients, Fine Chemicals, Crop Protection chemicals & CDMO

Speciality Chemicals Segment Highlights – Q1 FY’23 (Rs Crore)

Particulars ¹	Q1'FY22	Q1'FY23	YoY (%)
Revenue	305	382	26%
Reported EBITDA	84	64	(24%)
Reported EBITDA Margin (%)	27.7%	16.8%	

FINANCIAL HIGHLIGHTS

- Specialty Chemicals revenue grew by 26% on YoY basis driven by higher volume across product segments
- Specialty Volumes grew by 24% YOY basis
- Share of revenue to customers having Agro Chemical end use grew significantly.
- We also witnessed healthy demand for Oil field chemicals.


EBITDA:

- Segment EBITDA & Margin was lower mainly due to unprecedented and sharp increase in input costs including energy cost, which was passed on partially during the quarter.


BUSINESS HIGHLIGHTS

- Signed a CDMO contract worth Rs.270 Cr with a pharma innovator company to supply of two GMP intermediates.
- Our CDMO Pipeline is healthy and progressing positively. Our new GMP and non-GMP facilities which are expected to be ready during Q3FY’23, will help us in capture growing demand of CDMO projects.
- We observed positive traction of demand for our other Specialty chemicals also from both domestic as well as international customers due to China plus one strategy.

Q1'FY23 Geographical Revenue Split



Q1'FY23 Industry End-Use Split



*Industrial include Paints & Coatings, Print & Packaging, Solvents etc.
 **Consumer include Personal Care, Fragrances etc.


1. All figures are in Rs Crore unless otherwise stated
 3. Specialty Chemicals Segment comprises Specialty Ingredients, Fine Chemicals, Crop Protection chemicals & CDMO

Speciality Chemicals Segment Highlights – FY'22 (USD Million)


Particulars ¹	FY21 ²	FY22	YoY (%)
Revenue	145.6	180.4	24%
Reported EBITDA	34.8	40.5	16%
Reported EBITDA Margin (%)	23.9%	22.4%	

Products	Volume Growth FY'22
Specialty Chemical	16.0%

FY22 Geographical Revenue Split



FY22 Industry End-Use Split



*Industrial include Paints & Coatings, Print & Packaging, Solvents etc.
 **Consumer include Personal Care, Fragrances etc.

FINANCIAL HIGHLIGHTS

- Specialty Chemicals revenue grew by 24% on YoY basis driven by higher volume across products and new launches.
- Domestic revenue grew significantly, by 35% percentage share to total revenue increased to 32% from 27% during previous year
- Revenue in North American region increased by 36% on YoY.
- Revenue from customers having Nutrition, consumer and Industrial end-use grew significantly on YoY basis

EBITDA:

- EBITDA grew by 16% YoY.
- EBITDA Margin were at 22.4% vs 23.9% in FY21, impacted due to higher raw material prices and increase in other input costs.


1. All figures are in USD Million unless otherwise stated, translated on Convenience Conversion basis : USD 1 = Rs 77.18
 2. FY21 is derived on Pro-forma basis by combining reported discontinued operation results of LSI segment of Jubilant Pharmova Limited and audited results of company as explained in Slide 2
 3. Specialty Chemicals Segment comprises Specialty Ingredients, Fine Chemicals, Crop Protection Chemicals & CDMO

Speciality Chemicals Segment Highlights – FY'22 (Rs Crore)


Particulars ¹	FY21 ²	FY22	YoY (%)
Revenue	1,124	1,393	24%
Reported EBITDA	268	312	16%
Reported EBITDA Margin (%)	23.9%	22.4%	

Products	Volume Growth FY'22
Specialty Chemical	16.0%

FY22 Geographical Revenue Split



FY22 Industry End-Use Split



*Industrial include Paints & Coatings, Print & Packaging, Solvents etc.

**Consumer include Personal Care, Fragrances etc.

FINANCIAL HIGHLIGHTS

- Specialty Chemicals revenue grew by 24% on YoY basis driven by higher volume across products and new launches.
- Domestic revenue grew significantly, by 35% percentage share to total revenue increased to 32% from 27% during previous year
- Revenue in North American region increased by 36% on YoY.
- Revenue from customers having Nutrition, consumer and Industrial end-use grew significantly on YoY basis

EBITDA:

- EBITDA grew by 16% YoY.
- EBITDA Margin were at 22.4% vs 23.9% in FY21, impacted due to higher raw material prices and increase in other input costs.

1. All figures are in Rs Crore unless otherwise stated

2. FY21 is derived on Pro-forma basis by combining reported discontinued operation results of LSI segment of Jubilant Pharmova Limited and audited results of company as explained in Slide 2

3. Specialty Chemicals Segment comprises Specialty Ingredients, Fine Chemicals, Crop Protection Chemicals & CDMO

Nutrition & Health Solutions – Segment Snapshot

5 Nutrition Ingredients & 18+ branded solutions
(For Animal Health)

Global top 2 in Vitamin B3
Domestic leader in Vitamin B4 (Feed); Entered into **Human Business application** of Choline Chloride



100% in-house sourcing of Beta Picoline (Key RM) for Vitamin B3 via green route

20% Global market share in Vitamin B3;
69% domestic share in Vitamin B4

5 Plants across **2 Sites**

WHO GMP, FSSAI, HALAL, KOSHER and FAMI-QS certified

Revenue Segmentation (FY'22)



*Personal Care & Industrial applications

Animal Nutrition & Health Solutions Brands

Poultry	Dairy	Aqua
Liver Protection Solutions → ANICHOL PhytoShield	Milk Enhancer Solutions → ANICHOL-RP NUTRA PLUS	Gut Health Solutions → GLYMIN AQUA JUBIMIN PLUS-AQUA
Better Meat Quality → EnCroMix	Anti-Stress Solutions → EnCroMix	Feed Efficiency Solutions → Acifeed Aqua
Anti-Stress Solutions → Csmc Betaine EnCroMix	Milk Quality Solutions → JUBILYS RP JUBIMETS-RP	Feed Quality Solutions → Acifeed Aqua
Egg Quality Enhancer → "Egghancer"	Transition Health Solutions → NIACON RP	
Feed Quality Solutions → ToxiCOP Jubidol		
Feed Efficiency Solutions → JubiDOL		
Gut Health Solutions → ButyMAX Hi-Pro-Min		
Immunity Enhancer → NIACON Hi-Pro-Min		
Non - AGP Solutions → GROPLUS		

Niacinamide End Use Applications

Animal Feed	Pet Food	Hair Care	Cosmetics
Energy Drinks	Breakfast Cereal	Nutraceuticals	Weight Supplements

"Partner of Choice" to ~460 global customers and has established strong distribution network
Globally, we serve **90+** customers in Cosmetics, **55+** Customers in Dietary supplements & **20+** Customers for Energy Drinks and Breakfast Cereals.

Strategic partnership for the Human Nutrition line of products
More than half of the exports in regulated markets leading to sustainable revenue

In line with our Vision to double the revenue by FY'26, we have **18 Products** in Pipeline

Investment target of **~INR 200 Crores / USD 25.9 Mn** by FY'25

Nutrition & Health Solutions Segment Highlights – Q1 FY'23 (USD Million)

Particulars ¹	Q1'FY22	Q1'FY23	YoY (%)
Revenue	21.6	19.5	(10%)
Reported EBITDA	3.4	2.4	(29%)
Reported EBITDA Margin (%)	15.9%	12.5%	


FINANCIAL HIGHLIGHTS

- Nutritional Business sales was impacted mainly due to spread of Bird Flu and Swine Flu in Europe US region, coupled with lower consumption in China due to covid related lock down situation.
- Niacinamide volumes were down by 39% YOY basis


EBITDA

- EBITDA de-grew by 29% on YoY basis and EBIDTA margin decreased to 12.5 % vs 15.9% in Q1'FY22 mainly due to lower volume, while price realization has been better.

Q1'FY23 Geographical Revenue Split



Q1'FY23 Industry End-Use Split



BUSINESS HIGHLIGHTS

- Business witnessed a short-term challenge but maintains its market share and leadership position.
- Flu position in EU & America regions are improving and we expect normal demand to start during second half of the current quarter.
- We improved our market share in niche segments like Food & Cosmetics on YOY Basis.
- Our Animal Nutrition business has witnessed strong demand in India, Business has significantly improved volume and revenue from value added Specialty premixes.

1. All figures are in USD Million unless otherwise stated, translated on Convenience Conversion basis : USD 1 = Rs 77.18
 2. Nutrition & Health Solutions Segment comprises, Nutrition & Health Ingredients, Animal Nutrition & Health Solutions, Human Nutrition & Health Solution

Nutrition & Health Solutions Segment Highlights – Q1 FY'23 (Rs Crore)

Particulars ¹	Q1'FY22	Q1'FY23	YoY (%)
Revenue	167	150	(10%)
Reported EBITDA	27	19	(29%)
Reported EBITDA Margin (%)	15.9%	12.5%	


FINANCIAL HIGHLIGHTS

- Nutritional Business sales was impacted mainly due to spread of Bird Flu and Swine Flu in Europe US region, coupled with lower consumption in China due to covid related lock down situation.
- Niacinamide volumes were down by 39% YOY basis


EBITDA

- EBITDA de-grew by 29% on YoY basis and EBITDA margin decreased to 12.5 % vs 15.9% in Q1'FY22 mainly due to lower volume, while price realization has been better.

Q1'FY23 Geographical Revenue Split



Q1'FY23 Industry End-Use Split



BUSINESS HIGHLIGHTS

- Business witnessed a short-term challenge but maintains its market share and leadership position.
- Flu position in EU & America regions are improving and we expect normal demand to start during second half of the current quarter.
- We improved our market share in niche segments like Food & Cosmetics on YOY Basis.
- Our Animal Nutrition business has witnessed strong demand in India, Business has significantly improved volume and revenue from value added Specialty premixes.


1. All figures are in Rs Crore unless otherwise stated
 2. Nutrition & Health Solutions Segment comprises, Nutrition & Health Ingredients, Animal Nutrition & Health Solutions, Human Nutrition & Health Solution

Nutrition & Health Solutions Segment Highlights – FY'22 (USD Million)


Particulars ¹	FY21 ²	FY22	YoY (%)
Revenue	81.6	99.4	22%
Reported EBITDA	16.9	21.3	26%
Reported EBITDA Margin (%)	20.7%	21.4%	-

Products	Volume Growth FY'22
Niacinamide	9.0%

FY22 Geographical Revenue Split



FY22 Industry End-Use Split



FINANCIAL HIGHLIGHTS

- Nutrition and Health Solutions revenue grew by 22% on YoY basis.
 - Growth of Vitamin Business was driven by higher volumes and improved prices .
 - Animal Nutrition and Health solution business also improved volumes and realization YOY.
- Revenue in North America and EU grew significantly by 78% and 65% respectively.
- Food and cosmetics revenue has gone up significantly with 48% and 56% respectively.

EBITDA

- EBITDA grew by 26% on YoY basis. EBITDA Margin stood at 21.4% , EBITDA improved on account of better realization and higher volumes .


1. All figures are in USD Million unless otherwise stated, translated on Convenience Conversion basis : USD 1 = Rs 77.18
2. FY21 is derived on Pro-forma basis by combining reported discontinued operation results of LSI segment of Jubilant Pharmova Limited and audited results of company as explained in Slide 2
3. Nutrition & Health Solutions Segment comprises, Nutrition & Health Ingredients, Animal Nutrition & Health Solutions, Human Nutrition & Health Solution

Nutrition & Health Solutions Segment Highlights – FY'22 (Rs Crore)


Particulars ¹	FY21 ²	FY22	YoY (%)
Revenue	630	767	22%
Reported EBITDA	130	164	26%
Reported EBITDA Margin (%)	20.7%	21.4%	-

Products	Volume Growth FY'22
Niacinamide	9.0%

FY22 Geographical Revenue Split



FY22 Industry End-Use Split



FINANCIAL HIGHLIGHTS

- Nutrition and Health Solutions revenue grew by 22% on YoY basis.
 - Growth of Vitamin Business was driven by higher volumes and improved prices .
 - Animal Nutrition and Health solution business also improved volumes and realization YOY.
- Revenue in North America and EU grew significantly by 78% and 65% respectively.
- Food and cosmetics revenue has gone up significantly with 48% and 56% respectively.

EBITDA

- EBITDA grew by 26% on YoY basis. EBITDA Margin stood at 21.4% , EBITDA improved on account of better realization and higher volumes .

1. All figures are in Rs Crore unless otherwise stated
2. FY21 is derived on Pro-forma basis by combining reported discontinued operation results of LSI segment of Jubilant Pharmova Limited and audited results of company as explained in Slide 2
3. Nutrition & Health Solutions Segment comprises, Nutrition & Health Ingredients, Animal Nutrition & Health Solutions, Human Nutrition & Health Solution

Chemical Intermediates – Segment Snapshot

9 Products

(Acetic Anhydride, Ethyl Acetate, Propionic Anhydride, Aldehydes, Speciality Alcohol, Anhydrous Alcohol, Green Acetic Acid)

Acetic Anhydride:

Globally No. 2 in Merchant Mkt
No.1 in India
Expected to be **Global leader** by FY'24

Entered Value added derivative **Propionic Anhydride** to **Replace all imports in India;** Also enter international Market


Ethyl Acetate: Among top 2 in Domestic market

19 plants across **3** Sites (Multi-location, Multi-plant advantage)

Products are REACH, HALAL & KOSHER certified


Region wise Revenue Segmentation

For Segment (FY'22)



Diverse Industry End-Use

FY'22 End Use Split



Pharmaceuticals	Artificial Sweeteners	Agro
Cellulose Acetate	Modified Starch	Packaging & Coatings
Polyimide Films	Wood Acetylation	Vitamins

“Partner of Choice” to ~570 global customers European Union is the major deficit market: nearly 90% import dependent for Acetic Anhydride; nearly 70% import dependent for Ethyl Acetate.

India Pharma and Agro applications are estimated to witness strong growth, mainly driven by Paracetamol, Acephate and Ibuprofen.

Shift of manufacturing from China to India will encourage growth in various industrial applications in India.

In line with our Vision to double the Revenue by FY'26, we have **7 Products** in Pipeline

Investment target of ~ **INR 620 Crores / USD 80.3 Million** by FY'25

Chemical Intermediates Segment Highlights – Q1 FY’23 (USD Million)

Particulars ¹	Q1'FY22	Q1'FY23	YoY (%)
Revenue	87.2	82.0	(6%)
Reported EBITDA	23.8	9.9	(58%)
Reported EBITDA Margin (%)	27.3%	12.1%	


FINANCIAL HIGHLIGHTS

- Chemical Intermediates business continue to witness strong demand resulting into robust volume growth.
- Acetic Anhydride volumes grew by 22% on YOY basis.
- Segment revenue de-grew by 6% on YoY basis mainly due to lower input price i.e Acetic Acid price which is now stabilizing.
- Revenue from Europe & Japan have gone up significantly on YoY basis.


EBITDA

- On YoY basis segment has witnessed normalized market situation as well as lower Acetic Acid prices, which is also reflecting into both Revenue as well as EBITDA

Q1'FY23 Geographical Revenue Split



Q1'FY23 Industry End-Use Split



BUSINESS HIGHLIGHTS

- We continue to maintain domestic market leadership for Acetic Anhydride and remained the key supplier of Ethyl Acetate.
- Our market share in Europe has improved significantly and is continuing to grow.
- We are witnessing good traction of demand for our new product i.e Propionic Anhydride
- Our upcoming Acetic Anhydride plant at Bharuch is under construction and is expected to be ready during Q4'FY23.

1. All figures are in USD Million unless otherwise stated, translated on Convenience Conversion basis : USD 1 = Rs 77.18

2. Chemical Intermediates Segment comprises, Life Science Ingredients and Speciality Ethanol

Chemical Intermediates Segment Highlights – Q1 FY'23 (Rs Crore)

Particulars ¹	Q1'FY22	Q1'FY23	YoY (%)
Revenue	673	633	(6%)
Reported EBITDA	184	76	(58%)
Reported EBITDA Margin (%)	27.3%	12.1%	


FINANCIAL HIGHLIGHTS

- Chemical Intermediates business continue to witness strong demand resulting into robust volume growth.
- Acetic Anhydride volumes grew by 22% on YOY basis.
- Segment revenue de-grew by 6% on YoY basis mainly due to lower input price i.e Acetic Acid price which is now stabilizing.
- Revenue from Europe & Japan have gone up significantly on YoY basis.


EBITDA

- On YoY basis segment has witnessed normalized market situation as well as lower Acetic Acid prices, which is also reflecting into both Revenue as well as EBITDA

Q1'FY23 Geographical Revenue Split



Q1'FY23 Industry End-Use Split



BUSINESS HIGHLIGHTS

- We continue to maintain domestic market leadership for Acetic Anhydride and remained the key supplier of Ethyl Acetate.
- Our market share in Europe has improved significantly and is continuing to grow.
- We are witnessing good traction of demand for our new product i.e Propionic Anhydride
- Our upcoming Acetic Anhydride plant at Bharuch is under construction and is expected to be ready during Q4'FY23.


1. All figures are in Rs Crore unless otherwise stated
 2. Chemical Intermediates Segment comprises, Life Science Ingredients and Speciality Ethanol

Chemical Intermediates Segment Highlights – FY'22 (USD Million)


Particulars ¹	FY21 ²	FY22	YoY (%)
Revenue	225.1	361.4	61%
Reported EBITDA	30.6	54.0	77%
Reported EBITDA Margin (%)	13.6%	14.9%	

Products	Volume Growth FY'22
Acetic Anhydride	3.0%
Ethyl Acetate	-19.0%

FY22 Geographical Revenue Split



FY22 Industry End-Use Split



FINANCIAL HIGHLIGHTS

- Chemical Intermediates revenue grew by 61% on YoY basis
 - Chemical Intermediates revenue growth was driven by higher prices and volume growth in Acetic Anhydride.
 - Prices improvement was mainly on account of favorable market condition.
 - Revenue from sales in EU region have gone up significantly by 130% on YoY basis.
 - Share of sales from EU increased to 15% from 11% in FY21

EBITDA

- EBITDA grew by 77%. Margin stood at 14.9%. Growth in EBITDA margin was driven by
 - Improved product contribution driven by favorable market conditions of Acetic Anhydride.
 - Improved pricing of Ethyl Acetate also contributed to margin expansion.


1. All figures are in USD Million unless otherwise stated, translated on Convenience Conversion basis : USD 1 = Rs 77.18
 2. FY21 is derived on Pro-forma basis by combining reported discontinued operation results of LSI segment of Jubilant Pharmova Limited and audited results of company as explained in Slide 2
 3. Chemical Intermediates Segment comprises, Life Science Ingredients and Speciality Ethanol

Chemical Intermediates Segment Highlights – FY'22(Rs Crore)


Particulars ¹	FY21 ²	FY22	YoY (%)
Revenue	1,738	2,789	61%
Reported EBITDA	236	417	77%
Reported EBITDA Margin (%)	13.6%	14.9%	

Products	Volume Growth FY'22
Acetic Anhydride	3.0%
Ethyl Acetate	-19.0%

FY22 Geographical Revenue Split



FY22 Industry End-Use Split



FINANCIAL HIGHLIGHTS

- Chemical Intermediates revenue grew by 61% on YoY basis
 - Chemical Intermediates revenue growth was driven by higher prices and volume growth in Acetic Anhydride.
 - Prices improvement was mainly on account of favorable market condition.
 - Revenue from sales in EU region have gone up significantly by 130% on YoY basis.
 - Share of sales from EU increased to 15% from 11% in FY21

EBITDA

- EBITDA grew by 77%. Margin stood at 14.9%. Growth in EBITDA margin was driven by
 - Improved product contribution driven by favorable market conditions of Acetic Anhydride.
 - Improved pricing of Ethyl Acetate also contributed to margin expansion.

1. All figures are in Rs Crore unless otherwise stated
 2. FY21 is derived on Pro-forma basis by combining reported discontinued operation results of LSI segment of Jubilant Pharmova Limited and audited results of company as explained in Slide 2
 3. Chemical Intermediates Segment comprises, Life Science Ingredients and Speciality Ethanol



Outlook & Growth Plans

- We expect overall healthy revenue growth during FY'23, led by volume growth in Specialty Chemicals & Chemical intermediate business segment. Commissioning of our three new capex of CDMO GMP, CDMO non-GMP and Acetic Anhydride is likely to aid the revenue growth.
- In the Nutrition & Health Solution segment Niacinamide demand is expected to start normalizing in the later part of the current quarter
- We expect our EBIDTA of subsequent quarters of FY'23 to improve, assuming no unexpected adverse situation
- We are fully committed towards our growth aspirations and we are excited to realise the emerging opportunities through our ongoing Growth Capex plan of Rs 2,050 Crore / USD 265.6 Mn during FY'22 to FY'25 Period.
- We are strategizing towards improving our revenue mix of Specialty and Nutrition segments to 65% by FY'26 from 46% in FY'22 and we believe this to be a key driver for overall margin improvements.

Growth Capex Investment Plan – Business Wise (USD Million)

(Already Committed & to be Committed)

Committed till date ~ USD 116.6 Million
(From FY'22 to Q1'FY23, Total Cash Outflow ~ USD 40.4 Million.)

Expected Peak Revenue of USD 246.2 Million
From USD 116.1 Million Investment

Speciality Chemicals

- **CDMO (GMP) Multipurpose plant**– For Pharma intermediates (Q3 FY'23)
- **CDMO (Non-GMP)** Two Multipurpose plant for Pharma & Agro intermediates (Q3 FY'23)
- **MPP Agro Active plant** – Moving up the value chain of Crop Protection actives & Growing customer demand (Q3 FY'24)

Note- Diketene Phase 1 is already commissioned

Chemical Intermediates

- **Acetic Anhydride capacity expansion** – Growing demand & Geographic expansion (Q4 FY'23)

Note- Food Grade Acetic Acid is already commissioned

Additional Capex to be Committed during FY'23 & FY'24~ USD 149.0 Million
Estimated Cash Outflow

~ (USD 61.3 Mn, USD 84.2 Mn. & USD 77.7 Mn. respectively in FY'23 – remaining year, FY'24 & FY'25)

Intended to be funded through internal accruals

Expected Peak Revenue of USD 336.9 Million
From USD 149.0 Million Core Investment

Speciality Chemicals

Proposed Investment: USD 87.5 Million

- The above proposed Investment is for expansion of – **Diketene Derivatives, Agrochemical Intermediates, and new green field GMP Plant for CDMO**
- Also proposed to be invested in new plants for foraying into **Fluorination Derivatives and Agro Actives (Fungicides)**

Nutrition & Health Solutions

Proposed Investment: USD 25.9 Million

- The above proposed investment will be done to set up – **GMP complaint Plant for Pharma Grade Vitamin B3, and Plants for enhancing portfolio of Animal & Human Nutrition products.**

Chemical Intermediates

Proposed Investment: USD 35.6 Million

- The above proposed investment will be done to set up a **Grain based Green Specialty Ethanol Plant & Other De-Bottlenecking .**

: Expected Peak revenue on Prices prevailed at the end of FY22. All figures are in USD Million unless otherwise stated, translated on Convenience Conversion basis : USD 1 = Rs 77.18

Growth Capex Investment Plan – Business Wise (Rs Crore)

(Already Committed & to be Committed)

Committed till date ~ Rs. 900 Crores
(From FY'22 to Q1'FY23, Total Cash Outflow ~ Rs.312 Cr.)

Expected Peak Revenue of Rs. 1900 Crores
From Rs. 900 Crore Investment

Speciality Chemicals

- **CDMO (GMP) Multipurpose plant**– For Pharma intermediates (Q3 FY'23)
- **CDMO (Non-GMP)** Two Multipurpose plant for Pharma & Agro intermediates (Q3 FY'23)
- **MPP Agro Active plant** – Moving up the value chain of Crop Protection actives & Growing customer demand (Q3 FY'24)

Note- Diketene Phase 1 is already commissioned

Chemical Intermediates

- **Acetic Anhydride capacity expansion** – Growing demand & Geographic expansion (Q4 FY'23)

Note- Food Grade Acetic Acid is already commissioned

: Expected Peak revenue on Prices prevailed at the end of FY22.

Additional Capex to be Committed during FY'23 & FY'24~ Rs. 1150 Crores
Estimated Cash Outflow
~ (Rs.473 Cr, Rs.650 Cr. & Rs.600 Cr. respectively in FY'23 – remaining year, FY'24 & FY'25)
Intended to be funded through internal accruals

Expected Peak Revenue of Rs. 2600 Crores
From Rs. 1,150 Crore Investment

Speciality Chemicals

Proposed Investment: Rs 675 Crores

- The above proposed Investment is for expansion of – **Diketene Derivatives, Agrochemical Intermediates, and new green field GMP Plant for CDMO**
- Also proposed to be invested in new plants for foraying into **Fluorination Derivatives and Agro Actives (Fungicides)**

Nutrition & Health Solutions

Proposed Investment: Rs 200 Crores

- The above proposed investment will be done to set up – **GMP complaint Plant for Pharma Grade Vitamin B3, and Plants for enhancing portfolio of Animal & Human Nutrition products.**

Chemical Intermediates


Proposed Investment: Rs 275 Crores

- The above proposed investment will be done to set up a **Grain based Green Specialty Ethanol Plant & Other De-Bottlenecking .**

Capacity Build- Up Plan – FY'22 to FY'25 (over Base of FY'22)


Overall Capacity Build-Up

Capacity Expansion Plan
(Overall capacity increase : 40.5% & CAGR: 12.0%)




Speciality Chemicals Capacity Build-Up

Capacity Expansion Plan
(Overall capacity increase: 44.7% & CAGR: 13.1%)




Nutrition & Health Solutions Capacity Build-Up

Capacity & Expansion Plan
(Overall capacity increase: 42.4% & CAGR: 12.5%)



Chemical Intermediates Capacity Build-Up


Capacity & Expansion Plan
(Overall capacity increase: 40.3% & CAGR: 11.9%)



The capacity added during the year has been considered on Annualized Basis

Structural Shift towards Speciality via Growth Capex Plans (USD Million)

Speciality & Nutrition will be 65% of Revenue up from present 46% post commissioning of our announced growth capex plans




- For committed investment of USD 116.6 Mn all plants will be operational by FY'24. For additional investment of USD 149.0 Mn, all plants will be ready by FY'25.
- In addition to this we would also have growth in revenue from existing facilities.

: Expected Peak revenue on Prices prevailed at the end of FY22. All figures are in USD Million unless otherwise stated, translated on Convenience Conversion basis : USD 1 = Rs 77.18

Structural Shift towards Speciality via Growth Capex Plans (Rs Crore)

Speciality & Nutrition will be 65% of Revenue up from present 46% post commissioning of our announced growth capex plans



- For committed investment of Rs 900 Cr all plants will be operational by FY'24. For additional investment of 1,150 Cr, all plants will be ready by FY'25.
- In addition to this we would also have growth in revenue from existing facilities.

: Expected Peak revenue on Prices prevailed at the end of FY22.



QUALITY














**BUSINESS
EXCELLENCE**



SUSTAINABILITY

Jubilant Ingrevia: Global Accreditation



Select Certifications	Gajraula	Bharuch	Nira	Samlaya	Ambernath
 Responsible Care RC 14001:2015	✓	✓	✓		
 ISO 9001:2015	✓	✓	✓	✓	✓
 ISO 22000:2005	✓	✓	✓		
 ISO 14001:2015	✓	✓	✓	✓	
 ISO 45001:2018	✓	✓	✓	✓	
 FSSAI	✓	✓	✓	✓	
 FAMI-QS		✓		✓	
 HALAL KOSHER	✓	✓	✓		
 GMP Certification	✓ State FDA GMP	✓ State FDA GMP & WHO GMP			
 ISO 50001	✓	✓			
 TFS Audit		✓ (FY'19)	✓ (FY'20)		
ISO/IEC 17025- NABL	✓	✓			



Certification for Jubilant Life Sciences Ltd.: FY'20 (Gold Category)

Business Excellence and Digital Transformation



Belt Competencies (FY'22)

Black Belts: 07

Green Belts: 103

Yellow Belts: 95

Business Excellence (18+ years experience)

Tools & Processes

Design Excellence

Strengthen Development Capability by exploring complete design space and target Right First Time

Theory of Constraints

Quality by Design

Mission Directed Team

Balanced Scorecard

Operational Excellence

- Removing process inefficiencies
- improve cost effectiveness
- Addressing process variation
- Improve asset utilization

Six Sigma

Lean

TPM

Process Engineering

Customer Excellence

- Effective time & cost management for customer's NPD projects
- Analytics for accurate forecasting

CRM

Analytics

Stage Gate deployment

Customer Dashboard

Digital Transformation

- Our journey started in 2018 with an objective to improve
 - Operational efficiency
 - Business & Supply chain processes
 - customer experience and engagement
- Every project we consider is based on the individual business case



Sustainability

- Energy Demand Forecasting
- Electronic Production Management
- Demand & Production Planning
- Digitally Accelerated Contract Manufacturing



Efficiency Improvement

- Upgradation & Security enhancement of ERP
- Process Automation
- Employee Collaboration
- Digital Factory



Customer Engagement

- Customer Experience
- Digital Sales through Salesforce Automation & Project & Workflow Management Platforms

Bring Progressive Social Change via Strategic Multi-Stakeholder Partnership

Established in 2007

Mission: To develop multi-stakeholder sustainable models to bring about 'social change' involving knowledge generation & sharing, experiential learning & entrepreneurial ecosystem

1 Million lives

Aspiring to touch the Lives through social initiatives

*

Education

Improving Health

Escalating Employability

Rural Development

Social Entrepreneurship

FACE- Centre for Excellence



- Benefitting over **100,000 students** in **500 govt. primary schools** through **E-Muskaan** (School Digitization), **Kushiyon Ki Pathshala** (Value education), **Muskaan Fellowship** (Youth Leadership programme)

- Providing affordable basic & preventive health care to over **6.5 Lakh populations** in **437 villages** through **Jubilant Aarogya** (Providing affordable healthcare, **Swasthya Prahari** (Preventive Health care) enabled with **JUBICARE-Tele-clinic** platform)

- Working towards providing Sustainable livelihood to **10000 family** through **Nayee Disha** (Skill Development), **Samridhhi** (SHG & micro enterprise Promotion), **Jubifarm** (Sustainable Agriculture programme)


- Jansanchetna** : Resource mapping and disseminating Emergency Preparedness plan with neighboring community at all plant locations
- Rural Infrastructure Support:** As and when required supporting rural infra like Water ATM, Hand pumps, Pond reclamation, School Building, Community Toilet, etc

- JBF with the **Schwab Foundation** recognize & award **exceptional individuals** in **Social Business**
- Providing business to social enterprises


An initiative between **CII & Jubilant Bhartia** to improve productivity of agriculture and increase farmer income



Sustainability Journey



OH&S Journey



SDG: Key Achievements

- 58% Reduction in Specific Water Consumption wrt FY'13
- 34% Reduction in Specific Greenhouse Gas Emissions wrt FY'13
- 34% Reduction in Specific Energy Consumption wrt FY'13
- 54486 Training man-days were imparted from FY'14

ESG Assessment



First time participated in S&P DJSI Assessment:

- Achieved **81 %ile** in the Global Chemical Industry
- Among the **top 20% companies globally**
- Among **top 3 Indian Chemical companies** in ESG score

For more details, visit our Sustainability page: <https://jubilantingrevia.com/about-us/sustainability>



The Economic Times recognized JVL as India's top company for Sustainability and CSR 2021



Global chemical industry's EHS initiative & Ethical framework towards safe chemicals management and performance excellence



S&P Global for DJSI 2021: Top 3 Indian Chemical companies in ESG

2019 National Energy Conservation Award
Logistics & Supply Chain Awards 2019

2018 FICCI Safety Award
FICCI Water Award

2016 FICCI Chemicals & Petrochemicals Awards
2016 CII Excellence in Energy Award



Our Vision, Values, Promise and Philosophy

OUR VISION

- To acquire and maintain global leadership position in chosen areas of businesses
- To continuously create new opportunities for growth in our strategic businesses
- To be among the top 10 most admired companies to work for
- To continuously achieve a return on invested capital of at least 10 points higher than the cost of capital

OUR PROMISE

Caring, Sharing, Growing

We will, with utmost care for the environment and society, continue to enhance value for our customers by providing innovative products and economically efficient solutions; and for our stakeholders through growth, cost effectiveness and wise investment of resources

OUR VALUES



OUR PHILOSOPHY



Caring



Sharing



Growing

For More Information



For Investors:

Surajit Pal

Ph: +91 120 436 1002

E-mail: Surajit.pal1@jubl.com

Pavleen Taneja

Ph: +91 120 436 1021

E-mail: pavleen.taneja@jubl.com

Thank you for your time

Jubilant Ingrevia Limited

1A, Sector-16A, Noida - 201 301, Uttar Pradesh, India

Email: support@jubl.com | www.jubilantingrevia.com

Appendix I: Income Statement – Q1'FY23 (USD Million)

Particulars ¹	Q1'FY22	Q1'FY23	YoY (%)
Total Revenue from Operations	148.3	151.1	2%
Speciality Chemicals	39.5	49.6	26%
Nutrition & Health Solutions	21.6	19.5	(10%)
Chemical Intermediates	87.2	82.0	(6%)
Total Expenditure	111.8	132.8	19%
Other Income	0.8	1.3	69%
Segment EBITDA			
Speciality Chemicals	10.9	8.3	(24%)
Nutrition & Health Solutions	3.4	2.4	(29%)
Chemical Intermediates	23.8	9.9	(58%)
Unallocated Corporate (Expenses)/Income	-0.9	-1.1	(17%)
Reported EBITDA	37.2	19.6	(47%)
Depreciation and Amortization	4.1	4.1	(1%)
Finance Cost	1.7	0.5	(68%)
Profit before Tax (After Exceptional Items)	31.5	15.0	(52%)
Tax Expenses (Net)	9.7	4.7	(52%)
PAT	21.8	10.3	(53%)
EPS - USD/Share	0.14	0.06	(53%)
Segment EBITDA Margins			
Speciality Chemicals	27.7%	16.8%	
Nutrition & Health Solutions	15.9%	12.5%	
Chemical Intermediates	27.3%	12.1%	
Reported EBITDA Margin	25.1%	12.9%	
Net Margin	14.7%	6.8%	

Appendix II: Income Statement – Q1'FY23 (Rs Crore)

Particulars ¹	Q1'FY22	Q1'FY23	YoY (%)
Total Revenue from Operations	1,145	1,166	2%
Speciality Chemicals	305	382	26%
Nutrition & Health Solutions	167	150	(10%)
Chemical Intermediates	673	633	(6%)
Total Expenditure	863	1,025	19%
Other Income	6	10	69%
Segment EBITDA			
Speciality Chemicals	84	64	(24%)
Nutrition & Health Solutions	27	19	(29%)
Chemical Intermediates	184	76	(58%)
Unallocated Corporate (Expenses)/Income	-7	-8	(17%)
Reported EBITDA	287	151	(47%)
Depreciation and Amortization	32	31	(1%)
Finance Cost	13	4	(68%)
Profit before Tax (After Exceptional Items)	243	116	(52%)
Tax Expenses (Net)	75	36	(52%)
PAT	168	79	(53%)
EPS - Face Value Re. 1 (Rs.)	10.6	5.0	(53%)
Segment EBITDA Margins			
Speciality Chemicals	27.7%	16.8%	
Nutrition & Health Solutions	15.9%	12.5%	
Chemical Intermediates	27.3%	12.1%	
Reported EBITDA Margin	25.1%	12.9%	
Net Margin	14.7%	6.8%	

1. All figures are in Rs Crore unless otherwise stated.

Appendix III: Income Statement – FY'22 (USD Million)

Particulars ¹	FY21 ²	FY22	YoY (%)
Total Revenue from Operations	452.3	641.3	42%
Speciality Chemicals	145.6	180.4	24%
Nutrition & Health Solutions	81.6	99.4	22%
Chemical Intermediates	225.1	361.4	61%
Total Expenditure	398.4	533.5	34%
Other Income	1.9	4.1	
Segment EBITDA			
Speciality Chemicals	34.8	40.5	16%
Nutrition & Health Solutions	16.9	21.3	26%
Chemical Intermediates	30.6	54.0	77%
Unallocated Corporate (Expenses)/Income	-1.0	-3.9	(278%)
Reported EBITDA	81.2	111.9	38%
Depreciation and Amortization	16.2	16.0	(1%)
Finance Cost	9.1	4.0	(56%)
Profit before Tax (After Exceptional Items)	54.2	91.9	69%
Tax Expenses (Net)	13.2	30.1	127%
PAT	41.0	61.8	51%
EPS - USD/Share	0.26	0.39	51%
Segment EBITDA Margins			
Speciality Chemicals	23.9%	22.4%	
Nutrition & Health Solutions	20.7%	21.4%	
Chemical Intermediates	13.6%	14.9%	
Reported EBITDA Margin	17.9%	17.4%	
Net Margin	9.1%	9.6%	

1. All figures are in USD Million unless otherwise stated, translated on Convenience Conversion basis : USD 1 = Rs 77.18

2. FY21 is derived on Pro-forma basis by combining reported discontinued operation results of LSI segment of Jubilant Pharmova Limited and audited results of company as explained in Slide 2
- EPS has been computed on combined profits assuming existence of share capital for full period.

Appendix IV: Income Statement – FY'22 (Rs Crore)

Particulars ¹	FY21 ²	FY22	YoY (%)
Total Revenue from Operations	3,491	4,949	42%
Speciality Chemicals	1,124	1,393	24%
Nutrition & Health Solutions	630	767	22%
Chemical Intermediates	1,738	2,789	61%
Total Expenditure	3,075	4,118	34%
Other Income	15	31	
Segment EBITDA			
Speciality Chemicals	268	312	16%
Nutrition & Health Solutions	130	164	26%
Chemical Intermediates	236	417	77%
Unallocated Corporate (Expenses)/Income	-8	-30	(278%)
Reported EBITDA	627	863	38%
Depreciation and Amortization	125	123	(1%)
Finance Cost	71	31	(56%)
Profit before Tax (After Exceptional Items)	418	709	69%
Tax Expenses (Net)	102	232	127%
PAT	316	477	51%
EPS - Face Value Re. 1 (Rs.)	19.9	30.0	51%
Segment EBITDA Margins			
Speciality Chemicals	23.9%	22.4%	
Nutrition & Health Solutions	20.7%	21.4%	
Chemical Intermediates	13.6%	14.9%	
Reported EBITDA Margin	17.9%	17.4%	
Net Margin	9.1%	9.6%	

1. All figures are in Rs Crore unless otherwise stated

2. - FY21 is derived on Pro-forma basis by combining reported discontinued operation results of LSI segment of Jubilant Pharmova Limited and audited results of company as explained in Slide 2
 - EPS has been computed on combined profits assuming existence of share capital for full period.